Antibody engineering, virus retargeting and cellular immunotherapy: One ring to rule them all?

Laura Sanz, Jian Qiao, Richard G. Vile, Luis Álvarez-Vallina

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Solid tumours present numerous obstacles for efficient systemic delivery of therapeutic agents. This goal has to face specific problems related to the nature of each targeting element, but also the physical barriers posed by tumours, such as heterogeneous blood supply and elevated interstitial pressure. These barriers impair the delivery to tumours of antibodies or viral particles. Immune cells are supposed to be endowed with the ability to target tumours, but in general, tumour cells themselves provide poor targets for immunological responses. A key challenge of tumour gene therapy (cell carrier- and/or viral vector-mediated) is to control the site at which genes are expressed by instructing cells or virus or to distinguish between target and non-target tissue. Thus, antibody-directed targeting of virus or cells could potentially improve both the safety and the efficacy of therapeutic gene delivery to tumours. Furthermore, virus production can rely on carrier cells under the transcriptional control of a factor activated after specific triggering of a tumour-specific receptor. Given that any of these anti-tumour strategies by themselves have fulfilled their therapeutic potential, we propose here their combination for developing more effective anti-cancer therapies.

Original languageEnglish (US)
Pages (from-to)63-70
Number of pages8
JournalCurrent Gene Therapy
Volume5
Issue number1
StatePublished - Feb 1 2005

Fingerprint

Immunotherapy
Viruses
Antibodies
Neoplasms
Neoplasm Antibodies
Architectural Accessibility
Therapeutics
Genetic Therapy
Virion
Genes
Safety
Pressure

Keywords

  • Antibody engineering
  • Cancer
  • Gene therapy
  • Virus targeting

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Drug Discovery
  • Genetics(clinical)

Cite this

Antibody engineering, virus retargeting and cellular immunotherapy : One ring to rule them all? / Sanz, Laura; Qiao, Jian; Vile, Richard G.; Álvarez-Vallina, Luis.

In: Current Gene Therapy, Vol. 5, No. 1, 01.02.2005, p. 63-70.

Research output: Contribution to journalReview article

Sanz, Laura ; Qiao, Jian ; Vile, Richard G. ; Álvarez-Vallina, Luis. / Antibody engineering, virus retargeting and cellular immunotherapy : One ring to rule them all?. In: Current Gene Therapy. 2005 ; Vol. 5, No. 1. pp. 63-70.
@article{b1424c39991a4f5b821dae9c6a642b78,
title = "Antibody engineering, virus retargeting and cellular immunotherapy: One ring to rule them all?",
abstract = "Solid tumours present numerous obstacles for efficient systemic delivery of therapeutic agents. This goal has to face specific problems related to the nature of each targeting element, but also the physical barriers posed by tumours, such as heterogeneous blood supply and elevated interstitial pressure. These barriers impair the delivery to tumours of antibodies or viral particles. Immune cells are supposed to be endowed with the ability to target tumours, but in general, tumour cells themselves provide poor targets for immunological responses. A key challenge of tumour gene therapy (cell carrier- and/or viral vector-mediated) is to control the site at which genes are expressed by instructing cells or virus or to distinguish between target and non-target tissue. Thus, antibody-directed targeting of virus or cells could potentially improve both the safety and the efficacy of therapeutic gene delivery to tumours. Furthermore, virus production can rely on carrier cells under the transcriptional control of a factor activated after specific triggering of a tumour-specific receptor. Given that any of these anti-tumour strategies by themselves have fulfilled their therapeutic potential, we propose here their combination for developing more effective anti-cancer therapies.",
keywords = "Antibody engineering, Cancer, Gene therapy, Virus targeting",
author = "Laura Sanz and Jian Qiao and Vile, {Richard G.} and Luis {\'A}lvarez-Vallina",
year = "2005",
month = "2",
day = "1",
language = "English (US)",
volume = "5",
pages = "63--70",
journal = "Current Gene Therapy",
issn = "1566-5232",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Antibody engineering, virus retargeting and cellular immunotherapy

T2 - One ring to rule them all?

AU - Sanz, Laura

AU - Qiao, Jian

AU - Vile, Richard G.

AU - Álvarez-Vallina, Luis

PY - 2005/2/1

Y1 - 2005/2/1

N2 - Solid tumours present numerous obstacles for efficient systemic delivery of therapeutic agents. This goal has to face specific problems related to the nature of each targeting element, but also the physical barriers posed by tumours, such as heterogeneous blood supply and elevated interstitial pressure. These barriers impair the delivery to tumours of antibodies or viral particles. Immune cells are supposed to be endowed with the ability to target tumours, but in general, tumour cells themselves provide poor targets for immunological responses. A key challenge of tumour gene therapy (cell carrier- and/or viral vector-mediated) is to control the site at which genes are expressed by instructing cells or virus or to distinguish between target and non-target tissue. Thus, antibody-directed targeting of virus or cells could potentially improve both the safety and the efficacy of therapeutic gene delivery to tumours. Furthermore, virus production can rely on carrier cells under the transcriptional control of a factor activated after specific triggering of a tumour-specific receptor. Given that any of these anti-tumour strategies by themselves have fulfilled their therapeutic potential, we propose here their combination for developing more effective anti-cancer therapies.

AB - Solid tumours present numerous obstacles for efficient systemic delivery of therapeutic agents. This goal has to face specific problems related to the nature of each targeting element, but also the physical barriers posed by tumours, such as heterogeneous blood supply and elevated interstitial pressure. These barriers impair the delivery to tumours of antibodies or viral particles. Immune cells are supposed to be endowed with the ability to target tumours, but in general, tumour cells themselves provide poor targets for immunological responses. A key challenge of tumour gene therapy (cell carrier- and/or viral vector-mediated) is to control the site at which genes are expressed by instructing cells or virus or to distinguish between target and non-target tissue. Thus, antibody-directed targeting of virus or cells could potentially improve both the safety and the efficacy of therapeutic gene delivery to tumours. Furthermore, virus production can rely on carrier cells under the transcriptional control of a factor activated after specific triggering of a tumour-specific receptor. Given that any of these anti-tumour strategies by themselves have fulfilled their therapeutic potential, we propose here their combination for developing more effective anti-cancer therapies.

KW - Antibody engineering

KW - Cancer

KW - Gene therapy

KW - Virus targeting

UR - http://www.scopus.com/inward/record.url?scp=13844272633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13844272633&partnerID=8YFLogxK

M3 - Review article

C2 - 15638711

AN - SCOPUS:13844272633

VL - 5

SP - 63

EP - 70

JO - Current Gene Therapy

JF - Current Gene Therapy

SN - 1566-5232

IS - 1

ER -